Prediction of Response to IUCD Associated Menorrhagia Using Doppler

Not Applicable

Completed

• Conditions: Women's Health: Amenorrhea/Dysmenorrhea
• Interventions: Device: Doppler

• Registration Number: NCT03794895
• Lead Sponsor: Ain Shams University

Brief Summary

Studying the efficacy of uterine artery doppler in predicting response to mefenamic acid in women having IUCD associated menorrhagia

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2017-05-01
• Primary Completion: 2018-05-01
• Study Completion: 2018-05-01
• Study First Submitted: 2018-12-27
• Status Verified: 2019-01
• Study First Submitted QC: 2019-01-03
• Last Update Submitted: 2019-01-03
• Study First Posted: 2019-01-07
• Last Update Posted: 2019-01-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 156

Inclusion Criteria

• women in chile bearing period (age 20-35 yrs ) with history of regular menstrual cycle presenting with recent onset of more then three months menorrhagia after IUCD "copper T 380 A" insertion

Read More

Exclusion Criteria

• history of bleeding tendency
• history of abnormal uterine bleeding due to other causes
• history of active liver disease
• history of antiplatelet or anticoagulant intake in the last month
• history of thyroid disease
• history of endometritis
• history of allergy to NSAIDs
• Adenomyosis
• women having contraindications to use NSAIDs e.g. peptic ulcer
• Insulin dependant diabetes mellitus

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Single arm clinical trial	Doppler	-

Primary Outcome Measures

Name	Time	Method
Resistance index and Pulsitality index (Predicting the response to IUCD associated menorrhagia)	1 year	Base line uterine artery doppler is done to the patient complaining of IUCD related menorrhagia prior to treatment , parameters of doppler are: resistance index and pulsitality index, then the patient takes mefenamic acid tablets 500 mg three times daily for five days, assessment of response whether the patient is responder or not is done using pictorial blood loss assessment chart then base line doppler parameters in responders and non responders are compared to correlate the response to base line doppler parameters

Trial Locations

Locations (1)

AinshamsU; 🇪🇬 Cairo, Abbaseya, Egypt